Management des Reizdarmsyndroms

Beim Reizdarmsyndrom handelt es sich um einen Symptomkomplex aus Schmerzen, Blähungen, Obstipation und Diarrhöen. Die Therapie ist nur symptomatisch.

Schlüsselwörter

Reizdarm - Bauchschmerz - Medikamentöse Therapie - Diarrhoe

• Literatur

• 1 Manning AP, Thompson WG, Heaton KW et al. Towards positive diagnosis of the irritable bowel. Br. Med. J 1978; 2: 653-654
• 2 Kruis W, Thieme C, Weinzierl M et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87: 1-7
• 3 Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut. 1999; 45 (Suppl. 02) 43-47
• 4 Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J. Gastrointest. Liver Dis. Jgld 2006; 15: 237-241
• 5 Layer P, Andresen V, Pehl C et al. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterol 2011; 49: 237-293
• 6 Andresen V, Keller J, Pehl C et al. Irritable Bowel Syndrome--The Main Recommendations. Dtsch. Ärzteblatt Int 2011; 108: 751-760
• 7 Hungin APS, Whorwell PJ, Tack J et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment. Pharmacol. Ther 2003; 17: 643-650
• 8 Larsson MH, Simrén M, Thomas EA et al. Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome. Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc 2007; 19: 812-820
• 9 Camilleri M, McKinzie S, Busciglio I et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol 2008; 6: 772-781
• 10 Kanazawa M, Palsson OS, Thiwan SIM et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am. J. Gastroenterol 2008; 103: 2550-2561
• 11 Bouin M, Plourde V, Boivin M et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-1777
• 12 Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201
• 13 Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand. J. Gastroenterol 1997; 32: 920-924
• 14 Goff BA, Mandel LS, Melancon CH et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. Jama J. Am. Med. Assoc 2004; 291: 2705-2712
• 15 Hamilton W, Peters TJ, Bankhead C et al. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ. 2009; 3339
• 16 Behtash N, Ghayouri Azar E, Fakhrejahani F. Symptoms of ovarian cancer in young patients 2 years before diagnosis, a case-control study. Eur. J. Cancer Care 2008; 17: 483-487
• 17 Fernández-Bañares F, Esteve M, Salas A et al. Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am. J. Gastroenterol 2007; 102: 2520-2528
• 18 Ford AC, Chey WD, Talley NJ et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch. Intern. Med 2009; 169: 651-658
• 19 Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the “no man's land” of gluten sensitivity. Am. J. Gastroenterol 2009; 104: 1587-1594
• 20 Van der Windt DAWM, Jellema P, Mulder CJ et al. Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. Jama J. Am. Med. Assoc 2010; 303: 1738-1746
• 21 Minderhoud IM, Oldenburg B, Wismeijer JA et al. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig. Dis. Sci 2004; 49: 469-474
• 22 García Rodríguez LA, Ruigómez A, Wallander MA et al. Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand. J. Gastroenterol 2000; 35: 306-311
• 23 Bohm M, Siwiec RM, Wo JM. Diagnosis and Management of Small Intestinal Bacterial Overgrowth. Nutr. Clin. Pract 2013; 28: 289-299
• 24 Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the Human Intestinal Microbial Flora. Science 2005; 308: 1635-1638
• 25 Hofmann AF. The syndrome of ileal disease and the broken enterohepatic circulation: cholerhetic enteropathy. Gastroenterology 1967; 52: 752-757
• 26 Wong BS, Camilleri M, Carlson P et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin. Gastroenterol. Hepatol. 2012; 10
• 27 Svendsen JH, Munck LK, Andersen JR. Irritable bowel syndrome--prognosis and diagnostic safety. A 5-year follow-up study. Scand. J. Gastroenterol 1985; 20: 415-418
• 28 Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann. Intern. Med 1995; 122: 107-112
• 29 Ford AC, Forman D, Bailey AG et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am. J. Gastroenterol 2008; 103: 1229-1239
• 30 Wegman HL, Stetler C. A meta-analytic review of the effects of childhood abuse on medical outcomes in adulthood. Psychosom. Med 2009; 71: 805-812
• 31 Ford AC, Talley NJ, Spiegel BMR et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008; 337
• 32 Guglielmetti S, Mora D, Gschwender M et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment. Pharmacol. Ther 2011; 33: 1123-1132
• 33 Ford AC, Talley NJ, Schoenfeld PS et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-378
• 34 Schäfer E, Ewe K. [The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon]. Fortschr. Med 1990; 108: 488-492
• 35 Andresen V, Layer P, Menge D et al. [Efficacy of freeze-dried Lactobacilli in functional diarrhoe: a pilot study]. Dtsch. Med. Wochenschr 2012; 137: 1792-1796
• 36 Keller J, Maier W, Layer P. Reizdarm-Patienten mit Meteorismus als dominantem Symptom profitieren von einer Therapie mit E. coli Nissle 1917– Ergebnisse einer Pilotstudie. Z. für Gastroenterol. 2010; 48
• 37 López-Alvarenga JC, Sobrino-Cossío S, Remes-Troche JM et al. Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: An analysis with pinaverium bromide 100mg plus simethicone 300mg po bid. Rev. Gastroenterol. México 2013; 78: 21-27
• 38 Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand. J. Gastroenterol 1996; 31: 463-468
• 39 Spiller RC. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome. Curr. Opin. Pharmacol 2011; 11: 68-74
• 40 Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med 2011; 364: 22-32
• 41 Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment. Pharmacol. Ther 2006; 23: 191-196
• 42 Camilleri M, Kerstens R, Rykx A et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N. Engl. J. Med 2008; 358: 2344-2354
• 43 Portalatin M, Winstead N. Medical management of constipation. Clin. Colon Rectal Surg 2012; 25: 12-19
• 44 Moore NA, Sargent BJ, Manning DD et al. Partial agonism of 5-HT3 receptors: a novel approach to the symptomatic treatment of IBS-D. Acs Chem. Neurosci 2013; 4: 43-47
• 45 Busby RW, Bryant AP, Bartolini WP et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur. J. Pharmacol 2010; 649: 328-335
• 46 Eutamene H, Bradesi S, Larauche M et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol. Motil 2010; 22
• 47 Rao S, Lembo AJ, Shiff SJ et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am. J. Gastroenterol 2012; 107: 1714-1724
• 48 Johnston JM, Kurtz CB, Macdougall JE et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010; 139